Section I: General Aspects<br>1. Pathophysiological aspects of calpains in cancer<br>2. Mitochondrial proteases in cancer development and progression<br>3. Proteases in Head and Neck Cancer<br>4. Matrix metalloproteases and uveal melanomas<br>5. Proteases in DNA damage, repair and radio resistance: Cellular and Molecular aspects<br>6. Radiotherapy, proteases and gastric cancer: a complex interplay<br>7. Matrix metalloproteases in the pathogenesis of hepatocarcinoma<br>8. Exploring synthetic and natural compounds for Cathepsin B: Mechanisms and therapy<br>9. Kallikrein-related peptidase 3 (KLK3) as valuable biomarkers for prostate cancer<br>10. Ubiquitin –specific protease 3,7 in bone cancer and squamous cell carcinoma<br>11. Serine protease: structure, classification, mechanism and role in breast cancer<br> <br>Section II: Proteases as Diagnostics and Prognostics Biomarkers<br>12. Protease activator receptor-1 and matrix metalloproteinase-1 as prognostic factors and novel therapeutic targets for gastric cancer<br>13. Matrix metalloproteases as diagnostic and prognostic biomarkers in cancer<br>14. From enzyme to predictors: Serine proteases in cancer diagnosis and prognosis<br>15. Cathepsins as a diagnostic and prognostic marker in Oral cancer<br>16. Role of Kallikreins in Prostate Cancer<br>17. Mechanistic aspects of Serine Protease as biomarkers in wound healing of lung cancer<br>18. The role of acetylcholinesterase in cancer development and possible therapeutic applications<br>19. Therapeutics of animal derived compounds in proteases induced cancer<br>20. Molecular Warriors: Proteases as Sentinels in the War Against Cancer Diagnosis and Prognosis<br> <br>Section III: Proteases, Chemoresistance and Cancer<br>21. Serine proteases, chemoresistance and cancer<br>22. Cathepsins, chemoresistance and cancer<br>23. ix metalloproteases, chemoresistance and cancer<br>24. MMPs (-2 and -9) mediated drug resistance and their reversal in gynecological cancer<br>25. The link between trypsinogen and chymotrypsinogen in gastrointestinal cancer<br>26. Role of the proteasome in the development of chemoresistance in multiple myeloma<br>27. Role of cysteine cathepsin and matrix metalloproteases in progression and chemoresistance in ovarian and breast cancer<br>28. Proteases, chemoresistance and cancer<br>29. Breaking Barriers: Proteases as Key Players in Cancer Chemoresistance<br> <br>Section IV: Other Aspects<br>30. Matrix metalloproteases-targeting low molecular weight compound<br>31. Synthetic protease inhibitors in oral, head and neck cancer: evidence from clinical trials.<br>32. Synthetic protease inhibitors in endocrine and gastroenterology cancers: results of clinical trials<br>33. Side effects of synthetic protease inhibitors used in gynecology cancers<br>34. Role of synthetic compounds with protease inhibitory activity in breast cancer<br>35. Cathepsin responsive nanomaterials for targeted delivery of malignant tumors
